KWD 2131

KWD 2131 is a beta-adrenoceptor agonist (beta-agonist) developed as a bronchodilator and anti-allergic agent. It exhibits both bronchodilating and anti-allergic activities, with studies showing dose-dependent inhibition of allergen-induced skin reactions and bronchodilation in patients with asthma or allergic conditions. Its mechanism of action is primarily through stimulation of beta-adrenoceptors, likely the beta-2 subtype, leading to relaxation of airway smooth muscle and inhibition of mediator release from mast cells. Compared to terbutaline, another well-known beta-agonist, KWD 2131 has similar but less potent effects[1][3][4][6]. The drug was investigated for its potential use in treating asthma and allergic responses but does not appear to have reached widespread clinical use.